Human C5-Binding Polypeptides for Lower-Weight Complement Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current C5-blocking agents, such as antibodies, are large and cumbersome, requiring frequent intravenous administration, causing side effects and being costly, and lack efficacy in animal models, necessitating the development of smaller, more effective alternatives.
Innovation Solution
Development of C5-binding polypeptides with specific amino acid sequences that exhibit high affinity for human C5, allowing for alternative therapeutic applications without the drawbacks of conventional antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used as C5-blocking agents, then C5 blockade efficacy is achieved, but molecular weight increases and administration frequency increases
Solution Approach 1:
The patent segments the antibody molecule into smaller functional units by using antibody fragments (such as Fab fragments, Fc fragments, or single-chain variable fragments) that retain C5 binding capability while reducing overall molecular weight. This allows maintaining therapeutic efficacy while decreasing the size of the therapeutic agent.
Solution Approach 2:
The patent extracts only the essential C5-binding functional regions from the full antibody structure, removing unnecessary portions such as the entire Fc region or constant domains, thereby obtaining minimal functional units that provide C5 blockade with reduced molecular weight.
2Reliability
If conventional antibodies are used as C5-blocking agents, then C5 blockade efficacy is achieved, but administration frequency increases
Solution Approach 1:
The patent modifies pharmacokinetic parameters by changing the molecular weight and structural properties of the C5-blocking agent, which affects clearance rates and half-life. Smaller molecules with optimized properties can have improved pharmacokinetic profiles, potentially reducing administration frequency while maintaining efficacy.
3Reliability
If conventional antibodies are used as C5-blocking agents, then C5 blockade efficacy is achieved, but cost increases
Solution Approach 1:
The patent employs smaller, less complex molecular structures that are more economical to produce, purify, and store compared to full antibodies. These reduced-size agents require smaller bioreactors, less cell culture material, and lower manufacturing overhead, thereby reducing production costs.
4Reliability
If conventional antibodies are used as C5-blocking agents, then C5 blockade efficacy is achieved, but animal model efficacy is insufficient
Solution Approach 1:
The patent designs C5-blocking agents with conserved binding epitopes that are present across multiple species, enabling the same molecular structure to effectively block C5 in both human and animal models. This universal design approach facilitates preclinical validation and potential translational applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These polypeptides provide effective C5 blockade with reduced molecular weight, improved administration flexibility, and cross-species efficacy, addressing the limitations of existing C5-blocking agents.
Implementation Method 1
C5-binding polypeptides with specific amino acid sequences that exhibit high affinity for human C5
Data Source
AI summary
The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected fromEX2X3X4A X6X7EID X11LPNL X16X17X18QW X21AFIX25 X26LX28D,andii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatments.